Madrigal Eyes Combination MASH Therapy with Pfizer Deal

Why It Matters

The partnership could solidify Madrigal’s leadership in the fast‑growing MASH market and unlock new revenue streams, while giving Pfizer a commercial outlet for its low‑priority asset.

Key Takeaways

• Madrigal licenses Pfizer’s ervogastat for $50M upfront.
• Combination aims to boost Rezdiffra’s MASH efficacy.
• Rezdiffra sales hit $287M Q3 2025, nearing $1B annual.
• Competitors include Novo Nordisk’s Wegovy GLP‑1 for MASH.
• Phase‑2 asset remains low‑priority at Pfizer.

Pulse Analysis

The metabolic dysfunction‑associated steatohepatitis (MASH) market is rapidly emerging as a multi‑billion‑dollar opportunity, driven by rising prevalence of non‑alcoholic fatty liver disease worldwide. Madrigal Pharma secured a first‑mover advantage with Rezdiffra, a THR‑beta‑selective agonist that received FDA approval in 2024 and has already demonstrated strong sales momentum. By leveraging its blockbuster trajectory, Madrigal is now positioned to expand its portfolio beyond monotherapy, addressing unmet clinical needs and capturing a larger share of the burgeoning liver‑disease segment.

Ervogastat, Pfizer’s oral DGAT‑2 inhibitor, blocks the final step of triglyceride assembly, reducing hepatic fat accumulation and inflammation. When combined with Rezdiffra’s dual action on fat storage and inflammatory pathways, the duo promises additive therapeutic benefit for patients with moderate to advanced fibrosis. This strategic pairing reflects a broader industry trend toward combination regimens that tackle complex metabolic pathways, especially as rivals like Novo Nordisk introduce GLP‑1 agonists such as Wegovy into the MASH arena. Madrigal’s decision to acquire ervogastat for $50 million upfront, plus future milestones, underscores its confidence in the scientific rationale and commercial upside.

For investors, the deal signals Madrigal’s aggressive push to cement its dominance in a market projected to generate tens of billions annually. The partnership not only diversifies Madrigal’s pipeline but also provides Pfizer with a viable route to monetize an otherwise low‑priority asset. As regulatory approvals expand globally and payer acceptance grows, the combined therapy could accelerate revenue growth, strengthen the company’s valuation, and set a benchmark for future MASH combination strategies.